In the current medical era, where innovation and efficiency are critical forces to success, the adoption of
personalized/precision medicine initiatives is the next step in advancing quality care, better patient outcomes, and higher payer satisfaction. Through the proper usage of genetic testing and a better understanding of biomarker indicators, precision medicine can be utilized to prevent diseases in high risk patients, increase HCP efficiency, and an increase in therapy cost effectiveness to better satisfy payers.
Despite these positive benefits, the adoption of these initiatives has been slow and there are still barriers to success. In many instances, there are not enough people to process the mass amount of information these data driven sciences create or critical patient data is either incomplete or inaccurate because of a reliance on digital tools for data collection.
Precision Medicine is still a developing medical science, but it has the potential to add lifesaving initiatives to many aspects of the pharma field. If genetic testing and biomarker indication techniques are used properly and on the right people, a massive impact can be made in the area of disease prevention.
Top Reasons to Attend
- Analyze how novel, innovative, and creative data driven medical systems are being developed to better patient outcomes and payer satisfaction
- Overcome common barriers to precision medicine acceptance and increase widespread adoption throughout your medical and commercial enterprise
- Understand how to integrate new, data driven sciences that increase HCP efficiency and improved patient outcomes on your brand therapeutic
- Review the latest achievements from top academic researchers and the impact these research studies will have on the future of precision medicine in the pharma business model
- Examine new patient care models and how best to convey their importance to both payer and HCP
- Build on knowledge of essential biomarker and geno-type based therapies and how best to apply them to current care models
- Gain an understanding of the future of pharmacogenomics and pharmacogenetics testing and the advantages to utilizing this advancing medical science within precision medicine
Who Should Attend
Primary Market:
- Personalized Healthcare/Medicine
- Precision Medicine/healthcare
- Translational Health/Medicine
- Diagnostic and Personalized Medicine R&D
- Combination Product R&D
- Quality Assurance and Control
- Submissions
- Genomics
- RWE
- Informatics
- Digital Health
- Digital Innovation
- Digital Medicine
- AI
- Bioinformatics
- Patient Solutions
- Patient Engagement
- Clinical Innovation
- Clinical Operations
Secondary Market:
- Digital Health Providers
- Translational Medicine Consultancies (e.g. Mckinsey and other large firms)
- Physician Networks
- Medical Diagnostics and Early Phase Testing Companies
- Digital Agencies
- Technology Providers
- Clinical Technology and Data Management Solution Providers
- Functional Service Provider
Speakers
- Richard Batchelder, Global Director, Commercial Personalized Medicine, Market Development, GENENTECH/ROCHE
- Shrividya Iyer, Executive Director, Oncology Global Real World Evidence (RWE) & US HEOR, EISAI US
- Amy Gorman, Global Precision Medicine Commercial Strategy Director, JANSSEN
- Andrea Stevens, Director, Precision Medicine Access Strategy Global Commercial Data Science, JANSSEN
- Claudia Dollins, Comparative Diagnostics and Precision Medicine, Executive Director, Regulatory Affairs, BRISTOL-MYERS SQUIBB
- Christopher O’Donnell, Vice President, Global Head Translational Medicine, Cardiovascular and Metabolism, NOVARTIS
- Naveen Babbar, Senior VP, Translational Medicine, PRELUDE THERAPEUTICS
- Dr. Nita Limdi, Associate Director, Hugh Kaul Precision, Medicine Institute, UAB
- Nikki Martin, Director of Precision, Medicine Initiatives, THE LUNGEVITY FOUNDATION
- Ruth Nussinov, Head, Computational Biology Section, NATIONAL INSTITUTE OF HEALTH
- Ernest Odame, Director, Global Evidence & Outcomes, Oncology, TAKEDA
- Aradhana Ghosh, MD, Head of RWE Strategy Implementation, GENENTECH/ROCHE
- Lynn Navale, VP, Biometrics, ALLOGENE
- Bert Gold, Founder and Principal Consultant, GOLD STANDARD GENETICS
Please fill in your name and email to receive the Forum Agenda of this event.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
